地特胰岛素——一种个体变异性更低的基础胰岛素
被引量:5
摘要
健康人群机体通过胰岛素分泌的严密调控使血浆葡萄糖浓度保持在正常水平,包括持续低浓度的基础胰岛素分泌和进餐引发的餐时胰岛素分泌。糖尿病胰岛素治疗中的最大挑战是尽可能地模拟正常个体生理模式的内源性胰岛素分泌的特点。基础胰岛素可通过抑制糖原和脂肪分解从而保证空腹及每餐问血糖正常平稳。
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2010年第7期558-560,共3页
Chinese Journal of Diabetes
参考文献22
-
1Heise T,Pieber T R.Towards peakless,reproducible and long-acting insulins.An assessment of the basal analogues based on isoglycaemic clamp studies.Diabetes Obes Metab,2007,9:648-659.
-
2Russell-Jones D.Insulin detemir:improving the predictability of glycaemic control.Int J Obes Relat Metab Disord,2004,28 Suppl 2:S29-S34.
-
3Lauritzen T,Faber O K,Binder C.Variation in 125I-insulin absorption and blood glucose concentration.Diabetologia,1979,17:291-295.
-
4Home P,Kurtzhals P.Insulin detemir:from concept to clinical experience.Expert Opin Pharmacother,2006,7:325-343.
-
5Heise T,Nosek L,R?nn B B,et al.Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.Diabetes,2004,53:1614-1620.
-
6Klein O,Lynge J,Endahl L,et al.Albumin-bound basal insulin analogues (insulin detemir and NN344):comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.Diabetes Obes Metab,2007,9:290-299.
-
7Danne T,Datz N,Endahl L,et al.Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes:results from a randomized,double-blind,controlled trial.Pediatr Diabetes,2008,9:554-560.
-
8Philis-Tsimikas A.An update on the use of insulin detemir,with a focus on type 2 diabetes (drug evaluation update).Expert Opin Pharmacother,2008,9:2181-2195.
-
9Lüddeke H J,Sreenan S,Aczel S,et al.PREDICTIVE-a global,prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes:baseline characteristics and predictors of hypoglycaemia from the European cohort.Diabetes Obes Metab,2007,9:428-434.
-
10Dornhorst A,Lüddeke H J,Sreenan S,et al.Safety and efficacy of insulin detemir in clinical practice:14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.Int J Clin Pract,2008,61:523-528.
同被引文献32
-
1杨文英.地特胰岛素治疗2型糖尿病的耐受性、安全性和依从性[J].中华糖尿病杂志,2009,1(1). 被引量:16
-
2陆菊明.地特胰岛素的临床实践:PREDICTIVE研究结果分析[J].中华糖尿病杂志,2010,2(1). 被引量:5
-
3Selam JL. How to measure glycemic instability? Diabetes Metab, 2000, 26:148-151.
-
4Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and in- sulin glargine in people with type 1 diabetes. Diabetes, 2004, 53..1614 1620.
-
5Luddeke HJ, Sreenan S, Aczel S, et al. PREDICTIVE-a global, prospective observational study to evaluate insulin det- emir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglyeaemia from the European cohort. Diabetes Obes Metab, 2007, 9:428-434.
-
6Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin add to a regimen of antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther, 2006, 28:1569 1581.
-
7Hermansen K, Davies W, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care, 2006, 29:1269-1274.
-
8GORDON J, POCKETT RD, TETLOW AP, et al. A comparison of intermediate and long - acting insulins in people with type 2 diabetes starting insulin :an observational database study [ J ]. Int J Clin Pract,2010,64(12) :1609 -1618.
-
9VIGNERI R, SQUATRITO S, SCIACCA L. Insulin and its analogs: actions via insulin and IGF receptors [ J ]. Acta Diabetol, 2010,47 (4) :271 - 278.
-
10POLLOCK RF, ERNY - ALBRECHT KM, KALSEKAR A, et al. Long- acting insulin analogs: a review of " real - world" effectiveness in patients with type 2 diabetes [ J ]. Curt Diabetes Rev,2011,7( 1 ) :61 -74.
引证文献5
-
1薛山.地特胰岛素强化治疗2型糖尿病的优势比较[J].中国城乡企业卫生,2012,27(2):53-54.
-
2牛晓红,孙衍,周瑞君,李莉,宋祺,司芹芹,金苗苗,李俊岩.应用动态血糖监测系统评价地特胰岛素作为基础胰岛素治疗的优越性[J].中国糖尿病杂志,2012,20(11):839-842. 被引量:7
-
3宗晓春,董陆玲,高春斌.3种胰岛素强化降糖方案治疗2型糖尿病的疗效观察[J].河北医科大学学报,2012,33(12):1372-1374. 被引量:5
-
4孙晓顺.地特胰岛素与中性鱼精蛋白锌胰岛素联合诺和龙对新诊断2型糖尿病患者血糖变异性影响的观察[J].中国糖尿病杂志,2013,21(1):85-87. 被引量:7
-
5吴军.2型糖尿病超重或肥胖患者口服降糖药联合地特胰岛素的临床研究[J].重庆医学,2014,43(24):3236-3238. 被引量:18
二级引证文献35
-
1庞家莲,蒙光义,王冬晓.地特胰岛素治疗2型糖尿病临床应用和疗效研究进展[J].医学信息(医学与计算机应用),2014,0(7):527-529. 被引量:1
-
2庞家莲,蒙光义,王冬晓.地特胰岛素治疗2型糖尿病的进展[J].广西医学,2014,36(6):787-791. 被引量:9
-
3李玲,王芬.基础胰岛素与空腹血糖变异性[J].药品评价,2014,0(11):40-43.
-
4古丽加那提.马斯开,李春岭.加用格列美脲对预混门冬胰岛素治疗的2型糖尿病患者血糖飘移及低血糖发生率的影响[J].实用糖尿病杂志,2014,10(4):38-39. 被引量:2
-
5吴军.2型糖尿病超重或肥胖患者口服降糖药联合地特胰岛素的临床研究[J].重庆医学,2014,43(24):3236-3238. 被引量:18
-
6孙燕,张红,李融.2型糖尿病患者尿微量白蛋白与血糖波动的关系[J].山东医药,2014,54(36):81-82. 被引量:3
-
7马泽军.动态血糖监测在糖尿病治疗中的应用[J].实用糖尿病杂志,2014,10(6):57-58.
-
8梅杰民.瑞格列奈治疗2型糖尿病合并动脉粥样硬化的临床疗效分析[J].中国继续医学教育,2015,7(6):216-217. 被引量:2
-
9王晔华,丰凌云,王仁山.基础胰岛素在2型糖尿病中的应用[J].实用糖尿病杂志,2015,11(2):62-64.
-
10任艳莉.二甲双胍治疗2型糖尿病的疗效观察[J].中国继续医学教育,2015,7(9):219-220.
-
1王舟.三种治疗方案,哪种适合您?[J].糖尿病之友,2007(10):45-45.
-
2刘超,王昆,徐书杭.糖尿病治疗的总趋势:胰岛素个体化治疗策略[J].临床药物治疗杂志,2013,11(1):6-7. 被引量:3
-
3张利方.自身免疫性胰腺炎实验诊断研究进展[J].华南国防医学杂志,2014,28(9):942-942. 被引量:3
-
4陈凤莲.Brugada综合征2例报告并文献复习[J].实用心电学杂志,2007,16(2):137-138.
-
5赵湘娥,叶太平.氨氯地平治疗不同年龄段高血压疗效观察[J].临床医学,2006,26(6):71-71. 被引量:1
-
6赵军明,柳亚娟,李春岭.2型糖尿病患者血清钾对糖脂代谢的影响[J].实用糖尿病杂志,2016,12(1):62-63.
-
7朱娅梅,董砚虎.为什么要补充基础胰岛素?[J].糖尿病之友,2008(9):26-27.
-
8陈松林,王艳昕,姚晓黎,梁颖茵.脑梗死合并多脏器功能不全的治疗[J].中国冶金工业医学杂志,2006,23(1):50-51.
-
9王菲菲,张玲,包玉倩.二甲双胍和格列吡嗪对新诊断2型糖尿病患者胰岛素分泌功能的影响[J].中国现代医生,2015,53(34):7-10. 被引量:1
-
10陈国良.格列美脲联合胰岛素治疗肥胖型2型糖尿病的作用分析[J].中国初级卫生保健,2015,29(1):115-116. 被引量:2